Similar articles

• Continuous-infusion vindesine in refractory carcinoma of the cervix: a phase II trial.

  Kavanagh JJ, Saul PB, Gershenson DM, Copeland LJ, Wharton JT. Kavanagh JJ, et al. Cancer Treat Rep. 1985 Nov;69(11):1317-8. Cancer Treat Rep. 1985. PMID: 4092193 No abstract available.
• Continuous venous infusion of vindesine in metastatic breast cancer: experience with a subcutaneously implanted system and portable pump.

  Amoroso D, Bertelli G, Pronzato P, Vidili MG, Gulisano M, Lionetto R, Rosso R. Amoroso D, et al. Anticancer Res. 1989 Jan-Feb;9(1):141-3. Anticancer Res. 1989. PMID: 2705743
• Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.

  Recchia F, Sica G, De Filippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S. Recchia F, et al. Anticancer Res. 2000 May-Jun;20(3B):1985-90. Anticancer Res. 2000. PMID: 10928138 Clinical Trial.
• Phase one study of twice-weekly vindesine.

  Mulder NH, Postmus PE, Sleijfer DT, de Vries EG, Willemse PH. Mulder NH, et al. Eur J Cancer Clin Oncol. 1985 Dec;21(12):1555-6. doi: 10.1016/0277-5379(85)90252-4. Eur J Cancer Clin Oncol. 1985. PMID: 3830734 No abstract available.
• Establishment of the standard regimen for non-small-cell lung cancer in Japan.

  Masuda N. Masuda N. Oncology (Williston Park). 2001 Jan;15(1 Suppl 1):13-8. Oncology (Williston Park). 2001. PMID: 11221016 Review.